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BACKGROUND. This study reviews the case-mix characteristics, management, and
outcomes of melanoma cases occuring in the U. S. within the last decade.
METHODS. Analyses of the National Cancer Data Base (NCDB) were performed on
cases diagnosed between 1985 through 1994. A total of 84,836 cases comprised of
cutaneous and noncutaneous melanomas were evaluated.
RESULTS. The percentages of melanomas that were cutaneous, ocular, mucosal, and
unknown primaries were 91.2%, 5.2%, 1.3%, and 2.2%, respectively. For cutaneous
melanomas, the proportion of patients presenting with American Joint Committee on
Cancer Stages 0, I, II, III, and IV were 14.9%, 47.7%, 23.1%, 8.9%, and 5.3%, respectively.
Factors associated with decreased survival included more advanced stage at diagnosis,
nodular or acral lentiginous histology, increased age, male gender, nonwhite race, and
lower income. Multivariate analysis identified stage, histology, gender, age, and in-
come as independent prognostic factors. For ocular melanomas, 85.0% were uveal,
4.8% were conjunctival, and 10.2% occurred at other sites. During the study period,
there was a large increase in the proportion of ocular melanoma patients treated with
radiation therapy alone. For mucosal melanomas, the distribution of head and neck,
female genital tract, anal/rectal, and urinary tract sites was 55.4%, 18.0%, 23.8%, and
2.8%, respectively. Patients with lymph node involvement had a poor prognosis. For
unknown primary melanomas, the distribution of metastases as localized to a region
or multiple sites at presentation was 43.0% and 57.0%, respectively. Surgical treatment
of patients with unknown primary site of the melanoma resulted in better survival
compared with no treatment.
CONCLUSIONS. Treatment of early stage cutaneous melanoma resulted in excellent
patient outcomes. In addition to conventional prognostic factors, socioeconomic
factors were found to be associated with survival. Cancer 1998;83:1664 –78.
© 1998 American Cancer Society.
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The common feature of all melanomas is the cell of origin, themelanocyte. Melanocytes are pigmented dendritic-like cells lo-
cated in various anatomic sites. These sites include the base of the
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epidermis, the eye, and in epithelia of the nasal cavity,
oropharynx, anus, vagina, and urinary tract. Cutane-
ous melanomas are much more prevalent than non-
cutaneous melanomas, which are comprised of ocular
and mucosal sites.
The incidence of cutaneous melanoma is increas-
ing at a greater rate than any other human cancer in
the U. S., and the increase in mortality is second only
to lung cancer.1 Since 1973, the incidence rate has
been rising 4% to 6% each year. In 1998, it is estimated
that approximately 41,600 new cases will be diagnosed
in the U. S.2 It is estimated that there will be 7200
deaths due to melanoma in the U. S., or 1 death every
hour and 13 minutes. Lifetime analysis reveals that
approximately 1 in 75 persons born in the year 2000
will develop a cutaneous melanoma during his or her
lifetime.3 One of the major factors associated with this
rise in the incidence of cutaneous melanomas is the
increased exposure of individuals to ultraviolet radia-
tion. Unlike cutaneous melanomas, the incidence of
both ocular and mucosal melanomas is believed to
have remained stable.4,5
The purpose of this article was to review the case-
mix characteristics, management, and outcomes of
melanoma in the U. S. for the last decade. This report
includes patients diagnosed with cutaneous, mucous
membrane, and ocular melanomas as well as melano-
mas of unknown primary sites. To depict these pat-
terns of treatment and survival, analyses were per-
formed on the National Cancer Data Base (NCDB), a
database of cancer registry information created by the
American College of Surgeons’ Commission on Cancer
(COC) and the American Cancer Society in 1987.6,7 All
acute care hospitals are invited to submit their cancer
registry data on an annual basis. For the most current
NCDB call for data, 1227 hospitals contributed 689,714
records, representing an estimated 57% of all newly
diagnosed cancer patients in 1994. Unlike single-insti-
tution studies, the NCDB registry data are able to
provide treatment and survival information on a very
large number of patients from a broad range of com-
munity-based and academic hospitals. These cancer
registry data are a direct reflection of the actual infor-
mation that is being compiled on these patients; for
this reason, the database at times contains a large
percentage of cases with unknown variables (such as
stage and grade) with no capacity to audit the infor-
mation.
Although cancer registries are planning to collect
records directly from physicians’ offices in the year
2000, the data in this article were not collected using
this protocol. Because certain early stage melanomas
can be diagnosed and treated in physicians’ offices, it
is possible that the counts in this article represent an
undersampling of these types of patients.
METHODS
Hospital-based cancer registries provide their data to
the NCDB through a computerized format.6 To ensure
standardization, the data are coded at the hospital
level according to the Data Acquisition Manual,8 the
third and fourth editions of the American Joint Com-
mittee on Cancer (AJCC) Manual for Staging of Can-
cer,9,10 and the second edition of the World Health
Organization’s International Classification of Disease
for Oncology (ICD-O 2).11
Cases to be included in this study were extracted
from the data base according to histology (ICD-O 2
melanoma codes M872–M879), year of diagnosis
(1985–1994), the patient’s having been diagnosed
and/or treated at the reporting hospital, and the pa-
tients’ having presented with a primary tumor (vs.
recurrent disease). An algorithm based on selected
patient and disease characteristics was employed to
identify and eliminate duplicate cases in which more
than one hospital submitted a record on the same
patient (e.g., a patient who received surgery at one
facility and radiation therapy at another).
AJCC staging, used to describe the extent of dis-
ease, was applied to melanomas of the skin. This stag-
ing system employs Breslow’s depth of penetration
and Clark’s level of invasion, regional lymph node
status, and the presence or absence of metastatic dis-
ease. (Breslow’s depth and Clark’s level were not avail-
able for separate analysis.) For selected analyses, stage
was grouped into early (Stages 0 –II) and advanced
(Stages III–IV). Melanomas involving the eyelid were
grouped with cutaneous melanomas. Although mela-
noma of the eyelid has a separate staging system, it is
equivalent to the staging system for cutaneous mela-
nomas. Histologies were classified as per ICD-O 2
codes. The four main histologic groupings, represent-
ing cutaneous melanomas, were: nodular (M8721),
lentigo maligna (M8742), superficial spreading
(M8743), and acral lentiginous (M8744) melanomas.
The remaining histologies were categorized as “other”
(e.g., melanoma, not otherwise specified [NOS],
amelanotic, desmoplastic, or spindle cell). Ocular mel-
anomas were lesions involving the conjunctiva and
uvea. Uveal melanomas involved tumors arising in the
iris, ciliary body, and choroid. AJCC staging was re-
corded for uveal melanomas. However, AJCC stage
groupings for conjunctival melanomas currently are
not recommended. Mucosal melanomas are mucous
membrane lesions arising in the head and neck, fe-
male genital tract, anal/rectal, and urinary tract. There
is no staging system for mucosal melanomas, but
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lymph node status was a data element collected by
cancer registries and analyzed in this report. Melano-
mas presenting as isolated metastatic lesions from
unknown primary sites (i.e., no documentation of aris-
ing from cutaneous, ocular, or mucosal primary mel-
anomas) were coded as “unknown primary melano-
mas” (according to ICD-O 2).11 The presentation of
these unknown primary melanomas as regional (i.e.,
lymph node) or distant metastasis (i.e., nonlymph
node) was determined from the General Summary
Stage (according to the Data Acquisition Manual)8 and
the presence of lymph node disease.
In addition to tumor site, histology, and staging,
data regarding patient characteristics including age,
gender, race/ethnicity, and income also were col-
lected. Patient income was based on the average fam-
ily income of the patient’s zip code of residence as per
the U. S. Census. Income was grouped into low (,
$20,000, which was approximately the lowest 10% of
all NCDB cancer cases), high ($ $47,000, which was
approximately the highest 10% of all NCDB cancer
cases), and a middle-income group ranging from
$20,000 – 46,999.6
In this report, treatment represents the first
course of cancer-directed therapy for the index dis-
ease. More detailed surgical information (e.g., margin
width) and subsequent management of persistent or
recurrent disease are not available.
All analyses were performed using SPSS soft-
ware.12 To determine changes across time, patient and
disease characteristics and treatment were broken
down by diagnostic year groupings (with 1985–1989
representing the earlier time period and 1990 –1994
the later time period). Case-mix and treatment vari-
ables were broken down further by patient and dis-
ease stratifications of interest, with chi-square statis-
tics performed on selected cross-tabulations.
Outcome information was calculated on pa-
tients diagnosed in the earlier time period only to
allow for sufficient follow-up. Annual survival rates,
illustrated through 5 years using the life tables
method, represent disease specific rates from the
date of diagnosis to the endpoint (defined as death
with cancer). Pairwise comparisons using the Wil-
coxon statistic were performed on selected survival
analyses to determine whether the stratifications
had significantly different survival rates. For cuta-
neous melanoma, those variables with significantly
different (P , 0.05) survival rates in the univariate
analyses were entered into a Cox proportional haz-
ards model of regression analysis to determine their
independent influence on survival.
RESULTS
Disease Characteristics
The anatomic site of melanomas changed little across
these two year groups (Table 1A). The vast majority of
melanomas originated in the skin (91.2% for all years),
with the next highest percentage being ocular (5.3%
for all years). Other melanoma sites included un-
known primary melanomas and mucous membrane
melanomas comprising 2.2% and 1.3% of all reported
melanomas, respectively. Among the unknown pri-
mary melanomas, 43.0% presented with regional (i.e.,
lymph node) metastasis and 57.0% presented with
distant metastasis. Among mucosal melanomas, the
incidence of head and neck, female genital, anal/rec-
tal, and urinary tract melanomas was 55.4%, 18.0%,
23.8%, and 2.8%, respectively.
The histologic and stage distributions for cutane-
ous melanomas are illustrated in Table 1B. A large
variety of histologic classifications were recorded.
Among these classifications, four represented the
more traditional “phenotypic” characteristics that
commonly are referred to in clinical practice, which
include lentigo maligna, superficial spreading, nodu-
lar, and acral lentiginous melanomas. There was no
difference in the incidence of these phenotypic cate-
gories between the two year groups. Among these four
categories for all years (excluding histologies classified
as “other”), the percentages of lentigo maligna, super-
ficial spreading, nodular, and acral lentiginous mela-
nomas were 21.4%, 57.6%, 18.9%, and 2.1%, respec-
tively. Histologies included in the group labeled
“other” comprised 53.4% of all the cutaneous mela-
noma cases. Of these “other” histologies, 92.5% were
“melanoma, NOS” cases, with the remaining repre-
senting unique, descriptive histologic features.
A large percentage of cutaneous melanomas were
diagnosed at a localized stage, with 85.7% being Stage
0 –II for all years (Table 1B). Although this percentage
changed little between 1985–1989 and 1990 –1994, the
proportion of early stage melanomas that were re-
ported as noninvasive (Stage 0) increased from 11.4%
in the earlier time period to 16.4% in the later time
period. For all years, the percentage of patients pre-
senting with localized invasive melanomas (Stage I
and II) was 70.8%. Patients who presented with re-
gional lymph node disease (Stage III) or metastatic
disease (Stage IV) at the time of their diagnosis was
8.9% and 5.3%, respectively, for all years. There was an
impressive decrease in the proportion of patients who
were not staged, dropping from 42.0% in 1985–1989 to
17.6% in 1990 –1994.
The stages at presentation for the different histol-
ogies of cutaneous melanoma (all years combined) are
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summarized in Table 1C. Lentigo maligna lesions were
predominantly Stage 0 or I lesions, which comprised
88.6%. For superficial spreading melanomas, the most
prevalent stage was Stage I (68.1%) followed by Stage
II lesions (19.7%). Nodular and acral lentiginous le-
sions were more aggressive according to their stage at
presentation. For both nodular and acral lentiginous
histologies, the most common presentation was Stage
II, representing 51.1% and 37.0% of these histologies,
respectively. In addition, both nodular and acral len-
tiginous lesions presented with higher percentages of
Stage III and IV disease compared with the other his-
tologies.
Among the 4522 ocular melanomas for all years,
3846 patients (85.0%) had uveal melanomas (Table
1A). Among these uveal melanomas, AJCC staging was
recorded in 2286 patients; the percentage of patients
with AJCC Stages I, II, III, and IV were 31.3%, 28.9%,
31.9%, and 7.4%, respectively. There were 216 patients
with conjunctival melanomas. The remaining 460 pa-
tients with ocular melanomas were classified as “oth-
er” and comprised cornea, NOS; retina; lacrimal
gland; orbit, NOS; overlapping lesion of the eye; and
eye, NOS.
There is no recommended AJCC stage groupings
for conjunctival melanomas, and no staging classifi-
cation for mucosal melanomas. However, when infor-
mation could be retrieved from the medical records,
the lymph node status of mucosal melanomas was
recorded. Among the 1074 mucosal melanomas for all
years, lymph node status was recorded in 28.4% of
cases (Table 2). This represented 305 cases, 40.3% of
which had positive lymph nodes and 59.7% of which
had negative lymph nodes. A breakdown of lymph
node status by site revealed that the incidence of
positive lymph nodes for head and neck, female gen-
ital tract, anal/rectal, and urinary tract melanomas
was 26.6%, 23.0%, 61.0%, and 11.1%, respectively. The
presence of positive lymph nodes in mucosal melano-
mas had a significant adverse effect on survival.
Patient Characteristics
Patient characteristics were broken down for all years
with respect to cutaneous, mucosal, ocular, and un-
known primary melanoma classifications in Table 3A.
Compared with other histologic groups, there was a
definite trend toward a skewing of older patients di-
agnosed with mucosal melanomas with 49.0% of pa-
tients being age $70 years. As one would expect, there
was a higher percentage of females (63.5%) than males
diagnosed with mucosal melanomas due to lesions
arising in the female genital tract. By contrast, there
TABLE 1A
Disease Sites by Diagnostic Year for Melanoma
1985–1989 1990–1994 Total: all years
Count Percent Count Percent Count Percent
Site
Cutaneous 29883 91.7 47464 90.9 77347 91.2
Mucous membrane 393 1.2 681 1.3 1074 1.3
Ocular 1647 5.1 2875 5.5 4522 5.3
Unknown primary site 675 2.0 1218 2.3 1893 2.2
Total 32598 100 52238 100 84836 100
Mucous membrane site
Head and neck 212 53.9 383 56.3 595 55.4
Female genital 75 19.1 118 17.3 193 18.0
Anal/rectal 93 23.7 163 23.9 256 23.8
Urinary 13 3.3 17 2.5 30 2.8
Total mucous membrane 393 100 681 100 1074 100
Ocular site
Uveal 1365 82.9 2481 86.3 3846 85.0
Conjunctival 86 5.2 130 4.5 216 4.8
Other site 196 11.9 264 9.2 460 10.2
Total ocular 1647 100 2875 100 4522 100
Unknown primary site at presentation
Regional metastasis 287 42.5 527 43.3 814 43.0
Distant metastasis 388 57.5 691 56.7 1079 57.0
Total unknown primary site at presentation 675 100 1218 100 1893 100
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was a higher percentage of males (65.8%) than females
diagnosed with unknown primary melanoma. With
respect to race/ethnicity, there was a larger percent-
age of African-American and Hispanic individuals di-
agnosed with mucosal melanomas compared with the
percentage of African-American and Hispanic patients
diagnosed with cutaneous, ocular, or unknown pri-
mary melanomas. Approximately 8.8% of patients
with mucosal melanomas were of African-American or
Hispanic race/ethnicity compared with a substantially
lower percentage of melanomas (,3%) of the other
sites. Levels of income (i.e., low, middle, and high)
between the various sites of melanoma were not sub-
stantially different. Levels of income were different for
early versus advanced stage within cutaneous mela-
noma, with 21.2% of low income patients presenting
with Stage III or IV disease compared with 14.6% of
high income patients.
An analysis of patient characteristics by histology
for cutaneous melanomas for all years is summarized
in Table 3B. There were large differences between
histologies with respect to age and race/ethnicity. A
larger percentage of older patients presented with len-
tigo maligna lesions compared with the other histol-
ogies; 76.7% of the patients diagnosed with lentigo
maligna were age $60 years compared with 33.5%,
46.5%, and 61.8% for superficial spreading, nodular,
and acral lentiginous histologies, respectively. With
regard to race/ethnicity, African Americans and His-
panics comprised 15.9% of all patients diagnosed with
acral lentiginous melanomas whereas individuals of
these racial/ethnic backgrounds comprised only 1.3%,
TABLE 1B
Histologic Classifications and AJCC “Combined” Staging by Diagnostic Year for Cutaneous Melanoma
1985–1989 1990–1994 Total: all years
Count Percent Count Percent Count Percent
Histology
Lentigo maligna 2779 9.3 4933 10.4 7712 10.0
Superficial spreading 8430 28.2 12318 26.0 20748 26.8
Nodular 2850 9.5 3969 8.4 6819 8.8
Acral lentiginous 177 0.6 592 1.2 769 1.0
Other 15647 52.4 25652 54.0 41299 53.4
Total 29883 100 47464 100 77347 100
“Combined” stagea
Stage 0 1970 11.4 6420 16.4 8390 14.9
Stage I 8742 50.4 18113 46.3 26855 47.6
Stage II 4026 23.2 9041 23.1 13067 23.2
Stage III 1635 9.4 3461 8.9 5096 9.0
Stage IV 956 5.5 2062 5.3 3018 5.3
Subtotal known stage 17329 100 39097 100 56426 100
Unknown stage 12554 42.0b 8367 17.6b 20921 27.0b
Total 29883 47464 77347
AJCC: American Joint Committee on Cancer.
a “Combined” stage represents pathologic stage, augmented by clinical stage in cases in which the pathologic stage was not available.
b Percentage was based on total cases.
TABLE 1C
“Combined” Stage by Histology by Site for Cutaneous Melanoma, All Years
Stage
Total Cases0 1 2 3 4
Cutaneous 14.9 47.6 23.2 9.0 5.3 100 56426
Lentigo maligna 51.9 36.7 8.2 2.5 0.7 100 5569
Superficial spreading 6.7 68.1 19.7 4.3 1.2 100 15572
Nodular 0.5 20.4 51.1 22.8 5.2 100 5106
Acral lentiginous 9.3 34.0 37.0 14.9 4.8 100 579
Other 14.8 43.8 22.7 10.3 8.4 100 29600
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1.2%, and 1.9% of patients diagnosed with lentigo
maligna, superficial spreading, or nodular melano-
mas, respectively. Levels of income were not substan-
tially different between these histologic classifications.
Treatment
The vast majority (91.5%) of cutaneous melanomas
were treated with surgery alone (Table 4). Surgery
alone also was the primary modality, but to a lesser
extent, for managing mucous membrane melanomas
(56.4%) and ocular melanomas (57.0%). A higher per-
centage of these noncutaneous melanoma patients
also received radiation therapy, either alone (25.7% of
ocular melanomas) or in combination with surgery
(19.3% of mucous membrane melanomas). Approxi-
mately 58% of patients with unknown primary mela-
nomas were treated surgically with or without radia-
tion therapy and/or chemotherapy for management of
the metastasis. However, a substantial percentage
(17.7%) received no treatment in the form of surgery,
radiation therapy, or chemotherapy. Although not
shown in Table 4, there were few changes across the
years in treatment for the various sites. However, sur-
gery with radiation therapy has been used with in-
creasing frequency for treating mucous membrane
melanomas (from 11.3% in 1985–1989 to 15.3% in
1990 –1994). The treatment of ocular melanomas also
demonstrated a large rise across these years in the
percentage treated with radiation therapy alone (from
17.4% to 30.4%). There was a concomitant drop in the
percentage of ocular melanomas treated with surgery
alone (from 60.6% to 55.2%). Information regarding
the use of biologic response modifier therapy was
recorded for 16,987 of these patients with melanoma.
Within this group, 498 patients (2.9%) received a bio-
logic response modifier as part of their treatment.
Survival
Disease specific survival analyses, performed on pa-
tients diagnosed between 1985–1989, indicated that
78.8% were alive 5 years after diagnosis (Table 5A).
When stratified by anatomic site, cutaneous melano-
mas had the highest 5-year survival rate (80.8%), fol-
lowed by ocular melanomas (74.6%). The proportion
of patients with mucous membrane melanoma who
survived 5 years was much lower (25.0%). Patients
with unknown primary site of the melanoma also had
a low survival rate, with only 29.1% alive at 5 years.
Mucosal melanomas were analyzed with respect
to site and lymph node status. Patients with head and
neck, female genital tract, and anal/rectal mucosal
melanomas had 5-year survival rates of 31.7%, 11.4%,
TABLE 2
Lymph Node Status by Diagnostic Year for Mucous Membrane Melanoma in which Lymph Nodes Were Examined
1985–1989 1990–1994 Total: all years
Count Percent Count Percent Count Percent
All cases
No positive lymph nodes 85 65.9 97 55.1 182 59.7
Positive lymph nodes 44 34.1 79 44.9 123 40.3
Total 129 100 176 100 305 100
Head and Neck
No positive lymph nodes 36 69.2 44 60.3 80 73.4
Positive lymph nodes 16 30.8 29 39.7 29 26.6
Total 52 100 73 100 109 100
Female genital tract
No positive lymph nodes 24 85.7 31 72.1 55 77.0
Positive lymph nodes 4 14.3 12 27.9 16 23.0
Total 28 100 43 100 71 100
Anal/rectal
No positive lymph nodes 19 44.2 20 35.1 39 39.0
Positive lymph nodes 24 55.8 37 64.9 61 61.0
Total 43 100 57 100 100 100
Urinary tract
No positive lymph nodes 6 100 2 66.7 8 88.9
Positive lymph nodes 0 0 1 33.3 1 11.1
Total 6 100 3 100 9 100
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and 19.8%, respectively. There were too few cases of
urinary tract melanomas for survival analyses. The
survival rate for head and neck mucosal melanoma
was significantly better (P , 0.05) than female genital
tract or anal/rectal mucosal melanomas. Combining
all sites, 96 patients were identified with known lymph
node status in cases diagnosed between 1985–1989.
Patients with positive lymph nodes had a poorer out-
come, demonstrated by a 5-year survival rate of 16.4%
compared with 38.7% for all patients with negative
lymph nodes. There were too few cases within the
positive lymph node group to perform statistical anal-
yses.
Patients with ocular melanomas had survival bro-
ken down between uveal and conjunctival sites. The
overall, 5-year survival for uveal and conjunctival mel-
anomas was 83.5% and 75.7%, respectively, which was
not significantly different. The majority of ocular mel-
anomas were of uveal origin. Among uveal melano-
mas, patients with AJCC Stages I, II, III, and IV had
survival rates of 83.9%, 84.9%, 64.4%, and 59.3%, re-
spectively (Fig. 1). All stage subgroups were signifi-
cantly different from each other.
Cutaneous melanoma survival rates were disag-
gregated by “combined” stage when staging informa-
tion was available in 13,547 patients (Fig. 2). For Stage
0 melanomas (also known as melanomas in situ), the
5-year survival rate was 96.0%. For localized, invasive
melanomas (representing Stages I and II), the survival
rates were 92.5% and 74.8%, respectively. Lymph node
positive Stage III patients had a survival rate of 49.0%,
whereas Stage IV patients with metastatic disease had
a survival rate of only 17.9% (Fig. 2). All stage sub-
groups were significantly different from each other.
A breakdown of cutaneous melanoma survival ac-
cording to histologic subtype is summarized in Table
5B. The 5-year survival rates for lentigo maligna, su-
perficial spreading, nodular, and acral lentiginous
TABLE 3A
Patient Characteristics by Anatomic Site for Melanoma, All Years
Cutaneous Mucosal Ocular Unknown primary site
Count Percent Count Percent Count Percent Count Percent
Age (yrs)
, 30 5398 7.0 10 0.9 149 3.3 104 5.5
30–39 11036 14.3 35 3.3 322 7.1 253 13.3
40–49 13500 17.4 108 10.1 619 13.7 316 16.7
50–59 13202 17.1 149 13.9 839 18.5 368 19.4
60–69 15778 20.4 244 22.7 1210 26.8 416 22.0
70–79 12574 16.2 306 28.5 980 21.7 299 15.8
801 5795 7.5 220 20.5 400 8.8 136 7.2
Unknown 64 0.1 2 0.2 3 0.1 1 0.1
Total 77347 100 1074 100 4522 100 1893 100
Mean age (yrs) 55.3 67.0 60.4 56.0
Gender
Male 42013 54.3 391 36.4 2352 52.0 1245 65.8
Female 35132 45.4 682 63.5 2158 47.7 646 34.1
Other/unknown 202 0.3 1 0.1 12 0.3 2 0.1
Total 77347 100 1074 100 4522 100 1893 100
Race/ethnicity
White non-Hispanic 72500 93.7 918 85.5 4168 92.2 1794 94.8
African-American, non-Hispanic 590 0.8 72 6.7 37 0.8 34 1.8
Hispanic (any race) 911 1.2 42 3.9 86 1.9 19 1.0
Other/unknown 3346 4.3 42 3.9 231 5.1 46 2.4
Total 77347 100 1074 100 4522 100 1893 100
Incomea
Low (, $20,000) 5634 7.3 137 12.8 526 11.6 192 10.2
Middle ($20,000–46,999) 56922 73.6 768 71.5 3350 74.1 1365 72.1
High ($$47,000) 10852 14.0 118 11.0 359 7.9 194 10.2
Unknown 3939 5.1 51 4.7 287 6.4 142 7.5
Total 77347 100 1074 100 4522 100 1893 100
a Income groupings based on the lowest (, $20,000) and highest ($$47,000) 10% of all cancer patients on the National Cancer Data Base data set.
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melanoma were 93.2%, 91.6%, 64.6%, and 66.4%, re-
spectively. All histologic subgroups were significantly
different from each other except the nodular and acral
lentiginous subgroups. One potential factor contrib-
uting to differences in survival between certain histo-
logic subtypes most likely is due to the distribution of
stages within each group. As indicated in Table 1C,
both the nodular and acral lentiginous melanoma
subtypes were comprised of a higher percentage of
Stage II, III, and IV cases compared with the lentigo
maligna and superficial spreading histologic subtypes.
When accounting for stage, patients with nodular mel-
anomas still fared significantly worse than individuals
with superficial spreading melanomas for all stages of
invasive disease (Table 5B). There were no significant
differences in survival for patients with superficial
TABLE 3B
Patient Characteristics by Histology for Cutaneous Melanoma, All Years
Lentigo maligna Superficial spreading Nodular Acral lentiginous
Count Percent Count Percent Count Percent Count Percent
Age (yrs)
, 30 44 0.6 1790 8.6 443 6.5 31 4.0
30–39 195 2.5 3885 18.7 908 13.3 56 7.3
40–49 550 7.1 4419 21.3 1114 16.3 91 11.8
50–59 1001 13.0 3687 17.8 1176 17.3 116 15.1
60–69 2163 28.0 3759 18.1 1398 20.5 196 25.5
70–79 2468 32.0 2340 11.3 1113 16.3 193 25.1
801 1286 16.7 860 4.1 659 9.7 86 11.2
Unknown 5 0.1 8 0.1 8 0.1 0 —
Total 7712 100 20748 100 6819 100 769 100
Mean age (yrs) 67.5 51.3 56.4 61.6
Gender
Male 4613 59.8 10451 50.4 4005 58.7 346 45.0
Female 3091 40.1 10231 49.3 2792 41.0 422 54.9
Other/unknown 8 0.1 66 0.3 22 0.3 1 0.1
Total 7712 100 20748 100 6819 100 769 100
Race/ethnicity
White non-Hispanic 7185 93.1 19586 94.4 6477 95.0 617 80.2
African-American, non-Hispanic 35 0.5 49 0.2 55 0.8 89 11.6
Hispanic (any race) 63 0.8 206 1.0 78 1.1 33 4.3
Other/unknown 429 5.6 907 4.4 209 3.1 30 3.9
Total 7712 100 20748 100 6819 100 769 100
Incomea
Low (, $20,000) 573 7.4 1361 6.5 577 8.5 101 13.2
Middle ($20,000–46,999) 5642 73.2 15378 74.1 5151 75.5 543 70.6
High ($$47,000) 1063 13.8 2876 13.9 776 11.4 84 10.9
Unknown 434 5.6 1133 5.5 315 4.6 41 5.3
Total 7712 100 20748 100 6819 100 769 100
a Income groupings based on the lowest (, $20,000) and highest ($$47,000) 10% of all cancer patients on the National Cancer Data Base data set.
TABLE 4
Treatment by Anatomic Site for Melanoma (All Years)
Surg only RT only CH only Surg1 RT Surg1 CH RT1 CH All three None Unknown Total Cases
Site
Cutaneous 91.5 0.7 0.5 1.4 1.5 0.3 0.4 3.0 0.7 100 77347
Mucous membrane 56.4 8.5 1.6 19.3 2.0 2.0 2.8 6.1 1.3 100 1074
Ocular 57.0 25.7 0.3 8.8 1.5 0.2 0.2 4.6 1.7 100 4522
Unknown primary 39.4 8.2 8.4 11.0 5.5 4.5 2.6 17.7 2.7 100 1893
Surg: surgery; RT: radiation therapy; CH: chemotherapy.
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spreading or lentigo maligna melanomas within
Stages I or II. There were too few patients with acral
lentiginous melanoma to analyze for survival differ-
ences.
Survival analyses by stage were performed with
respect to age, gender, race/ethnicity, and income for
cutaneous melanoma patients (Table 5C). Patients
were classified as presenting with “early” (Stages I and
II) or “advanced” (Stages III and IV) disease. Patients
age $60 years did significantly worse than patients age
,60 years, with 5-year survival rates of 81.4% and
90.1%, respectively, for patients with early stage dis-
ease. For patients with advanced stage disease, the
5-year survival rate of patients age $60 years (32.0%)
was significantly less than the rate of patients age ,60
years (40.5%). Males fared significantly worse than
females, with the two genders having 5-year survival
rates of 83.5% versus 90.5% for early stage and 32.7%
versus 43.7% for advanced stage disease, respectively.
In regard to race/ethnicity, white individuals had sig-
nificantly better survival compared with nonwhite in-
dividuals for early stage melanoma (86.8% and 74.0%,
respectively). For advanced melanoma, nonwhite pa-
tients fared worse than white patients, with a 5-year
survival rate of 33.9% compared with 36.6%, respec-
tively, although the difference was not statistically sig-
nificant. In regard to income, there was a significant
trend toward improved survival in patients with early
melanomas as income increased. In early melanomas,
the 5-year survival rates for patients with low income
versus high income were 83.2% and 90.9%, respec-
tively. For patients with advanced stage melanomas,
TABLE 5A
Five-Year, Disease Specific Survival for 1985–1989 Melanoma
Years after diagnosis
Cases P value1 2 3 4 5
All cases 93.1% 87.8% 84.2% 81.1% 78.8% 25795
Site
Cutaneous 94.1 89.3 85.9 83.0 80.8 23696
Mucous membrane 74.5 49.3 38.4 30.2 25.0 306
Ocular 96.4 89.2 84.6 79.2 74.6 1275
Unknown primary 51.7 41.1 34.9 31.6 29.1 518
Mucous membrane sitea
Head and neck 82.0 54.4 46.5 37.4 31.7 163 0.0034b
Female genital tract 68.1 40.1 26.3 21.1 11.4 59
Anal/rectum 61.6 44.0 27.4 19.8 19.8 74
Known lymph node status for mucous membrane
Positive 61.9 33.6 25.7 16.4 16.4 33
Negative 84.9 55.6 44.0 38.7 38.7 63
Ocular site
Conjunctival 100 94.6 86.4 86.4 83.5 64 ,0.0001c
Uveal 97.3 90.5 86.6 80.6 75.7 1062
Other ocular 88.8 78.8 70.3 66.5 63.2 149
A pairwise comparison of “combined” Stages I–IV showed that each stage is significantly different from all other three stages, using the Wilcoxon (Gehan) statistic.
a There were too few cases for the urinary tract for survival analyses.
b At the P , 0.05 level, all site subgroups were significantly different from each other except female genital tract and anal/rectum.
c At the P , 0.05 level, all site subgroups were significantly different from each other except conjunctival and uveal.
FIGURE 1. Five-year, disease specific survival by “combined” stage for 1985–
1989 uveal melanoma. (Note:“combined” stage represents pathologic stage, aug-
mented by clinical stage in cases in which the pathologic stage was not available)
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the 5-year survival rates for patients with low income
versus high income were 30.0% and 45.4%, respec-
tively, but the difference was not statistically signifi-
cant.
For cutaneous melanoma, age, gender, race, in-
come, stage, and histology indicated significantly dif-
ferent survival rates within their stratifications. These
six variables were entered into a Cox regression anal-
ysis as dichotomous variables (Table 5D). Age was ,60
or $60 years, gender was male or female, race was
white or minority individuals, income was individuals
in the lower 50% or the upper 50%, stage was early or
advanced, and histology was nodular and acral len-
tiginous (with low 5-year survival rates of 64.6% and
66.4%, respectively) or lentigo maligna and superficial
spreading (with high 5-year survival rates of 93.2% and
91.6%, respectively). Race was the only variable that
was not significantly associated with survival. The
strongest predictors were stage (with advanced dis-
ease having a 2.08 relative risk value) and histology
(with the classifications demonstrating lower survival
rates [nodular and acral lentiginous] having a 1.78
relative risk value). The relative risk values for the
remaining variables were 1.33 for males, 1.20 for pa-
tients age $60 years, and 1.12 for patients in the lower
50% income bracket.
The survival of patients determined to have me-
tastases from unknown primary sites were evaluated
with respect to regional versus distant disease at pre-
sentation. Patients with regional disease (i.e., lymph
node) had a 5-year survival rate of 46.3% compared
with a rate of only 15.8% for patients who presented
with distant (i.e., nonlymph node) sites of disease, a
statistically significant difference (P , 0.0001) (Table
5E). The survival of individuals with unknown primary
melanomas was analyzed further with respect to treat-
ment. Treatment was grouped into surgical resection
(with or without adjuvant treatment) or no treatment.
For all patients with unknown primary melanomas,
the 5-year survival rate for those patients undergoing
surgical resection (38.8%) was significantly better than
that for patients who received no treatment (19.6%).
This was broken down further into individuals with
regional (i.e., lymph node) or distant disease at pre-
sentation. For regional presentation, the 5-year sur-
vival rates for patients with surgical treatment versus
those with no treatment were 54.5% and 26.5%, re-
spectively (with the number of patients receiving no
treatment being too small for statistical comparisons).
For distant presentation, 5-year survival rates associ-
ated with surgical treatment versus no treatment were
20.3% and 15.9%, respectively, which represented a
statistically significant difference.
DISCUSSION
Based on hospital registry data during a 10-year pe-
riod, this report documents the relative percentages of
cutaneous and noncutaneous melanomas diagnosed
in .86,000 patients. To our knowledge, this represents
one of the largest databases comprising patient char-
acteristics, histology, staging, therapy, and survival for
melanomas. The last NCDB study of melanoma, re-
ported in 1994, reviewed 20,165 cases of cutaneous
melanoma.13 Prior to that, the American College of
Surgeons performed a Patient Care Evaluation study
of cutaneous and noncutaneous melanoma compris-
ing 11,904 patients that was reported in 1992.14 In the
current study, cutaneous melanomas comprised
91.2% of the cases, followed by ocular (5.3%), un-
known primary (2.2%), and mucosal (1.3%) melano-
mas. The peak age at diagnosis for cutaneous, ocular,
and unknown primary site of melanomas was between
ages 60 – 69 years. By contrast, for mucosal melano-
mas, the peak age of incidence was between ages
70 –79 years. There was a predominance of white in-
dividuals diagnosed with cutaneous, ocular, and un-
known primary site of melanomas, with African-
American or Hispanic individuals comprising only
5.4% and 3.4% of cases, respectively.
In discussing the results by anatomic site of ori-
gin, cutaneous melanoma patients represented the
majority of individuals in the data base, totaling 77,347
cases. Among the patients diagnosed between 1985–
FIGURE 2. Five-year, disease specific survival by “combined” stage for
1985–1989 cutaneous melanoma. (Note: “combined” stage represents patho-
logic stage, augmented by clinical stage in cases in which the pathologic stage
was not available)
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1989, the overall 5-year survival was 80.8%. As ex-
pected, survival was associated with stage. Stage 0 (in
situ melanoma) and Stage I disease were highly cur-
able, with 5-year survival rates of 96.0% and 92.5%,
respectively. Fortunately, 62.6% of patients diagnosed
with melanoma fell into these stage groups. Surgical
excision was the major therapeutic modality, em-
ployed in 94.8% of patients alone or in concert with
other modalities. Of the patients in this database who
had information regarding the administration of bio-
logic response modifier therapy, only 2.9% were
treated with this modality. Because of the recent find-
ings that interferon-a is an effective adjuvant therapy
after surgery for patients with Stage III disease, it is
anticipated that there will be an increase in the use of
this biologic response modifier in the future.15 More-
over, vaccine therapies have seen a resurgence of in-
terest in the management of patients with melano-
ma.16,17
Of interest was the association between histologic
subtype (i.e., lentigo maligna, superficial spreading,
nodular, and acral lentiginous) and survival. Both the
lentigo maligna and superficial spreading subgroups
presented with a higher percentage of earlier stage
disease (Stages 0 through II). By contrast, the nodular
and acral lentiginous subgroups presented with a
higher proportion of advanced disease (Stages III and
IV), underscoring the aggressive biology of these his-
tologic subtypes. Even when accounting for stage, the
nodular histologic subtype behaved more aggressively
than the lentigo maligna and superficial spreading
subgroups. These observations validate the continued
use of these histologic descriptions in the reporting of
pathologic diagnoses of melanomas. There have been
other histologic features that may account for the ob-
served differences in this report, including ulceration,
vertical growth phase, angiolymphatic invasion, mi-
totic activity, presence of infiltrating lymphoid cells,
and evidence of regression.18 –20 However, these fea-
tures were not recorded within the hospital cancer
registries from which the NCDB is drawn, and there-
fore could not be analyzed.
TABLE 5B
Five-Year, Disease Specific Survival of Histology by “Combined” Stage for 1985–1989 Cutaneous Melanoma
Years after diagnosis
Cases P value1 2 3 4 5
Histology for cutaneous cases
Lentigo maligna 99.1 97.4 96.2 94.8 93.2 2157 , 0.0001a
Superficial spreading 99.0 97.1 95.2 93.0 91.6 6761
Nodular 91.5 81.7 74.4 68.7 64.6 2267
Acral lentiginous 96.1 88.4 80.0 73.8 66.4 138
“Combined” stage by histology for cutaneous casesb
Stage 0c
Lentigo maligna 99.4 99.1 98.9 97.7 97.7 511 0.9355
Superficial spreading 100 100 100 98.8 96.0 229
Stage Id
Lentigo maligna 99.4 98.7 97.4 95.2 93.6 513 , 0.0001e
Superficial spreading 99.7 99.0 98.2 96.6 95.7 2772
Nodular 97.0 91.4 87.8 82.4 79.8 351
Stage IId
Lentigo maligna 100 98.1 95.0 90.4 85.1 122 , 0.0001e
Superficial spreading 99.2 95.0 90.8 85.1 81.3 753
Nodular 96.9 86.7 78.9 73.6 68.0 663
Stage IIIf
Superficial spreading 97.9 80.9 73.4 63.5 58.4 204 0.0040
Nodular 86.5 71.4 61.8 54.0 48.5 299
Stage IVf
Superficial spreading 63.3 58.5 47.6 44.7 44.7 60 0.0263
Nodular 52.1 33.6 22.2 17.2 13.6 87
a At the P , 0.05 level, all histologic subgroups were significantly different from each other except nodular and acral lentiginous.
b “Combined” stage represents pathologic stage, augmented by clinical stage in cases in which the pathologic stage not available.
c There were too few cases of Stage 0 nodular and acral lentiginous to be reported.
d There were too few cases of Stage I or Stage II acral lentiginous to be reported.
e At the P , 0.05 level, all histologic subgroups were significantly different from each other except lentigo maligna and superficial spreading.
f There were too few cases of Stage III or Stage IV lentigo maligna and acral lentiginous to be reported.
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Because of the NCDB’s large database of cuta-
neous melanoma patients, the effects of different
patient characteristics on survival could be evalu-
ated. Age $60 years was found to be an adverse
prognostic factor for both early stage and advanced
stage disease. Analysis of age by increasing decades
also demonstrated the same trend of decreased sur-
vival (data not shown). Deaths due to causes unre-
lated to melanoma were censored and only disease
specific survival data were calculated. Hence, co-
morbid conditions associated with increasing age
were unlikely to be reasons for decreased survival
from cutaneous melanoma.
Gender was found to be a significant prognostic
factor, with males having worse survival than fe-
males. This was true for both early stage and ad-
vanced stage patient groups. It is known that the
distribution of the anatomic origin of cutaneous
melanomas differs between males and females;
women have a higher percentage of extremity mel-
anomas, whereas males have a higher percentage of
truncal melanomas.21 The axial location of mela-
noma has been reported to be associated with a
worse prognosis.22 In the NCDB the percentage of
males and females with axial melanomas (i.e., head
and neck or truncal sites) was 64.8% and 39.1%,
respectively. The proportion of males with cutane-
ous melanomas of the extremities (i.e., arm/shoul-
der and leg/hip) was 39.2% compared with 55.4% for
females. The gender differences identified in this
database also may be related to hormonal influ-
ences on the prognosis of melanoma. With respect
to race/ethnicity, whites fared better than non-
whites (i.e., African Americans and Hispanics) for
early stages of melanoma. There was a trend toward
poorer survival in nonwhite patients who presented
with advanced melanoma compared with whites;
however, the numbers were too small to reach sta-
TABLE 5C
Five-Year, Disease Specific Survival by Patient Characteristics by Early versus Advanced “Combined” Stage for 1985–1989 Cutaneous Melanoma
Years after diagnosis
Cases P value1 2 3 4 5
Age (yrs)
Early stage
,60 99.2 96.8 94.6 92.1 90.1 6230 , 0.0001
$60 97.9 93.0 89.0 84.4 81.4 3760
Advanced stage
,60 75.3 59.2 49.8 44.7 40.5 1131 , 0.0001
$60 66.6 49.1 41.5 36.0 32.0 941
Gender
Early stage
Male 98.4 94.2 90.4 86.5 83.5 5194 , 0.0001
Female 99.0 96.7 94.6 92.2 90.5 4799
Advanced stage
Male 69.9 52.8 42.8 36.6 32.7 1306 0.0010
Female 73.8 57.6 51.7 47.9 43.7 767
Race/ethnicity
Early stage
White 98.7 95.4 92.5 89.2 86.8 9420 0.0001
Nonwhite 97.3 89.4 81.4 75.2 74.0 158
Advanced stage
White 71.7 54.7 46.0 40.8 36.6 1945 0.3202
Nonwhite 63.0 48.8 45.4 35.9 33.9 77
Income
Early stage
Low 98.5 93.7 90.1 85.5 83.2 631 , 0.0001a
Middle 98.6 95.3 92.2 89.0 86.5 7335
High 98.8 96.7 9.6 92.5 90.9 1578
Advanced stage
Low 66.7 45.7 37.5 33.6 30.0 202 0.0914
Middle 71.7 54.8 45.9 40.1 35.9 1491
High 71.1 58.2 50.8 47.8 45.4 283
“Early” stage represents “combined” Stages I and II, and “advanced” stage represents “combined” Stages III and IV.
a At the P , 0.05 level, all income subgroups were significantly different from each other.
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tistical significance. Also interesting was the differ-
ences in survival related to income levels. There was
a direct relationship between increasing income
level and improved survival in patients with early
stages of cutaneous melanoma. This trend also was
observed for advanced stage melanoma; however,
the numbers again were too small to reach statisti-
cal significance.
A multifactorial analysis was performed to deter-
mine which case-mix variables (AJCC stage, histologic
subtype, age, gender, race, and income) were predic-
tive of survival for cutaneous melanoma. The factors
that proved to be independent predictive factors for
survival, in decreasing order, were: stage, histology,
gender, age, and income. We are not aware of any
report documenting income as a prognostic factor for
cutaneous melanoma. In cross-tabulations, higher in-
come levels (i.e., low, middle, and high) were associ-
ated with lower stages of disease at presentation (data
not shown). Nevertheless, the multivariate analysis
demonstrated income to be an independent prognos-
tic factor in addition to stage, which indicates that the
effects of income on survival are due to influences
besides stage. These effects of income on melanoma
survival are unknown and should be investigated fur-
ther because it is a factor that potentially can be al-
tered.
For all years, there was a total of 4522 ocular
melanomas, 85.0% of which were uveal and 4.8% of
which were conjunctival lesions. Surgery has been the
mainstay of treatment over all years; however, there
was a significant increase in the use of primary radi-
ation therapy as the sole treatment between 1985–
1989 and 1990 –1994 (from 17.0% to 30.4%).
A total of 1074 mucosal melanomas was recorded
in the database. The overall, 5-year survival rate of
those patients diagnosed between 1985–1989 was only
25.0%. The most prevalent site of mucosal melanomas
was the head and neck region (55.4%), followed by
anal/rectal melanomas (23.8%). Surgery was the main
component of treatment in 80.5% of cases. The com-
bined approach of utilizing surgery plus radiation
therapy for mucosal melanomas involved 19.3% of
patients compared with 1.4% for cutaneous melano-
mas. Approximately one-third of patients with muco-
sal melanomas had positive lymph nodes when lymph
node status was known. The presence of positive
lymph nodes was associated with a 5-year survival of
16.4% compared with 38.7% for patients with negative
lymph nodes. These findings document the important
prognostic effect of lymph node status in mucosal
melanomas, which should be incorporated in any for-
mal staging system established for this disease entity.
Patients with unknown primary melanomas fared
poorly. The database contained information that per-
mitted identification of whether the patients pre-
sented with regional or distant metastases. If one as-
sumes that the predominant source of these unknown
primary melanomas arose from a cutaneous site that
spontaneously regressed, it is interesting to note that
the 5-year survival rate of patients with regional me-
tastasis (46.3%) was similar to the rate of survival for
patients with Stage III cutaneous melanoma (49.0%).
In addition, patients with distant metastases from un-
known primary sites had a 5-year survival rate (15.8%)
that was similar to the survival of Stage IV cutaneous
melanoma (17.7%). Despite the poor prognosis of this
category of patients, surgical treatment did result in a
significant 5-year benefit in this subgroup of patients
compared with the subgroup of patients given no
treatment. Although there most likely is a selection
bias in favor of patients who received surgical therapy
versus those who received no treatment, several re-
ports have observed that the surgical management of
patients with lymph node disease from unknown pri-
mary melanomas fared as well as patients with known
cutaneous primary sites.23 The data in this current
report appear to substantiate the potential benefit of
surgical resection of patients with isolated lymph
node or visceral disease from unknown primary mela-
nomas.
In summary, patients with cutaneous melanomas
fared much better than patients with noncutaneous
TABLE 5D
Patient and Disease Characteristics Influencing Disease Specific
Survival for 1985–1989 Cutaneous Melanoma
Variables entered




Stage (0–II vs. III–IV) , 0.0001 2.08 1.93 2.24
Histology (low vs.
high survival
rate)a , 0.0001 1.78 1.65 1.92
Age (yrs) (, 60 vs.
601) , 0.0001 1.20 1.12 1.28
Income (lower vs.
upper 50%) 0.0011 1.12 1.05 1.20
Gender (male vs.
female) , 0.0001 1.33 1.24 1.43
Race (white vs.
African American) 0.9971 —b —b —b
These results were obtained using Cox regression analysis.
a The cutaneous histologies with higher 5-year survival (lentigo maligna and superficial spreading, with
93.2% and 91.6% rates, respectively) were grouped together and compared with the histologies with
lower 5-year survival (nodular and acral lentiginous, with 64.6% and 66.4% rates, respectively).
b Not applicable because race was not significant.
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melanomas after treatment. Fortunately, the majority
of individuals with cutaneous melanomas present at
an early stage when therapy is highly successful in
achieving 5-year cure rates. The mainstay of therapy
for patients with melanomas of all sites has been sur-
gical excision, except for patients with ocular melano-
mas, in whom a significant trend toward primary ra-
diation therapy has been observed. Surgical resection
of isolated disease due to unknown primary site of the
melanomas should be instituted when medically fea-
sible because a subgroup of those patients fare well.
Hopefully, with a better understanding of the biologic
and socioeconomic factors influencing melanoma
treatment, the survival of patients with melanoma will
improve. In this regard, adjuvant strategies utilizing
biologic response modifiers after surgical resection
appear promising.
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